Stoke Therapeutics Inc. has announced the presentation of two-year natural history data from the FALCON study, which evaluated patients with Autosomal Dominant Optic Atrophy (ADOA). The results were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting. The FALCON study is the largest prospective natural history study of ADOA, a rare genetic disease that leads to progressive vision loss. Findings indicate that no significant anatomic changes in the retina were observed over two years, suggesting that retinal dysfunction may be reversible with treatment. These data have informed Stoke Therapeutics' ongoing clinical development of STK-002, a proprietary antisense oligonucleotide currently being evaluated in the Phase 1 OSPREY study as a potential disease-modifying therapy for ADOA.